blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2854759

EP2854759 - DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.10.2020
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  15.11.2019
FormerGrant of patent is intended
Status updated on  07.07.2019
FormerExamination is in progress
Status updated on  23.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
ratiopharm GmbH
Graf-Arco-Strasse 3
89079 Ulm / DE
[2015/15]
Inventor(s)01 / MEERGANS, Dominique
Seumestrasse 11
81379 München / DE
02 / LEUTNER, Dirk
Situlistrasse 66a
80939 München / DE
 [2015/15]
Representative(s)Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
[2019/51]
Former [2015/15]Aechter, Bernd
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Mauerkircherstraße 45
81679 München / DE
Application number, filing date13723415.916.05.2013
[2019/51]
WO2013EP01461
Priority number, dateEP2012000404124.05.2012         Original published format: EP 12004041
US20121347954924.05.2012         Original published format: US201213479549
[2015/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013174498
Date:28.11.2013
Language:EN
[2013/48]
Type: A1 Application with search report 
No.:EP2854759
Date:08.04.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 28.11.2013 takes the place of the publication of the European patent application.
[2015/15]
Type: B1 Patent specification 
No.:EP2854759
Date:18.12.2019
Language:EN
[2019/51]
Search report(s)International search report - published on:EP28.11.2013
ClassificationIPC:A61K9/00, A61K9/20, A61K31/437, A61K47/32, A61K47/38, A61P7/02
[2015/15]
CPC:
A61K9/2054 (EP,US); A61K31/4545 (EP,US); A61K9/0053 (EP,US);
A61K9/2018 (EP,US); A61K9/2027 (EP,US); A61P7/02 (EP);
A61K9/2095 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/15]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:DARREICHUNGSFORMEN MIT APIXABAN UND MATRIXFORMER[2015/15]
English:DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER[2015/15]
French:FORMES DE DOSAGE COMPRENANT APIXABAN ET UN AGENT DE FORMATION DE MATRICE[2015/15]
Entry into regional phase18.11.2014National basic fee paid 
18.11.2014Designation fee(s) paid 
18.11.2014Examination fee paid 
Examination procedure18.11.2014Examination requested  [2015/15]
28.07.2015Amendment by applicant (claims and/or description)
23.12.2016Despatch of a communication from the examining division (Time limit: M06)
21.06.2017Reply to a communication from the examining division
19.02.2019Despatch of a communication from the examining division (Time limit: M04)
10.05.2019Reply to a communication from the examining division
08.07.2019Communication of intention to grant the patent
06.11.2019Fee for grant paid
06.11.2019Fee for publishing/printing paid
06.11.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.12.2016
Opposition(s)21.09.2020No opposition filed within time limit [2020/48]
Fees paidRenewal fee
21.05.2015Renewal fee patent year 03
20.05.2016Renewal fee patent year 04
23.05.2017Renewal fee patent year 05
25.05.2018Renewal fee patent year 06
23.05.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.05.2013
AL18.12.2019
AT18.12.2019
CY18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MK18.12.2019
MT18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
TR18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
IE16.05.2020
LU16.05.2020
BE31.05.2020
CH31.05.2020
LI31.05.2020
[2022/32]
Former [2022/27]HU16.05.2013
AL18.12.2019
AT18.12.2019
CY18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MT18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
TR18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
IE16.05.2020
LU16.05.2020
BE31.05.2020
CH31.05.2020
LI31.05.2020
Former [2022/26]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
TR18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
IE16.05.2020
LU16.05.2020
BE31.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/24]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
IE16.05.2020
LU16.05.2020
BE31.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/20]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
IE16.05.2020
LU16.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/15]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
LU16.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/12]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/07]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
CH31.05.2020
LI31.05.2020
Former [2020/51]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/47]AL18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/40]AL18.12.2019
CZ18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/37]AL18.12.2019
CZ18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
PT13.05.2020
Former [2020/36]AL18.12.2019
CZ18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
PT13.05.2020
Former [2020/35]AL18.12.2019
CZ18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/32]AL18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/25]FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/23]FI18.12.2019
LT18.12.2019
LV18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/22]FI18.12.2019
LT18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/21]NO18.03.2020
Cited inInternational search[XI] WO2008031782  (GLAXO GROUP LTD et al.)
 [X] WO2011106478  (BRISTOL MYERS SQUIBB CO et al.)
 [XD] WO2010147978  (PFIZER et al.)
 [X] CN102058889  (DINGHAO WANG et al.)
 [AD] WO03026652  (BRISTOL MYERS SQUIBB CO et al.)
 [A]   VARMA M V S ET AL: "FACTORS AFFECTING MECHANISM AND KINETICS OF DRUG RELEASE FROM MATRIX-BASED ORAL CONTROLLED DRUG DELIVERY SYSTEMS", AMERICAN JOURNAL OF DRUG DELIVERY, ADIS INTERNATIONAL, AUCKLAND ; YARDLEY, PA, USA, vol. 2, no. 1, 1 January 2004 (2004-01-01), pages 43 - 57, XP008043047, ISSN: 1175-9038, DOI: 10.2165/00137696-200402010-00003

DOI:   http://dx.doi.org/10.2165/00137696-200402010-00003
by applicantWO03026652
 WO2006078331
 WO2007001385
 WO2010147978
   DUBERG, M.; NYSTR6M, C.: "Studies on direct compression of tablets VI. Evaluation of methods for the estimation of particle fragmentation during compaction.", ACTA PHARM. SUEC., vol. 19, 1982, pages 421 - 436
   HUMBERT-DROZ P.; MORDIER D.; DOELKER E.: "Methode rapide de determination du comportement a la compression pour des etudes de preformulation", PHARM. ACTA HELV., vol. 57, 1982, pages 136 - 143
   YORK, P., DRUG DEV. IND. PHARM., vol. 18, 1992, pages 677
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.